Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095433 | 1.00 | CES2 (0.58) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL19592309 | 0.81 | CES2 (0.58) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL17894211 | 0.80 | CES2 (0.62) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL2097828 | 0.79 | CES2 (0.52) | CES2P2RX1GAA | |
| SCHEMBL10842400 | 0.79 | CES2 (0.67) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL33123 | 0.79 | NQO2 (0.58) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL28795999 | 0.78 | ALDH1A1 (0.65) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL7447900 | 0.78 | CES2 (0.64) | CES2SRD5A2ALDH1A1LMNANPSR1 | |
| SCHEMBL20924840 | 0.78 | CES2 (0.59) | CES2SRD5A2ALDH1A1MAOBLMNA | |
| SCHEMBL16474147 | 0.77 | MAPK14 (0.50) | ALDH1A1MAOBNPSR1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606255-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2098508-A1 | Cyclic derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| EP-1606255-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1606255-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | CES2 2825/4885SRD5A2 1027/4885ALDH1A1 1195/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | CES2 2992/4885SRD5A2 1001/4885ALDH1A1 1039/4885 |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CES2 2825/4885SRD5A2 1027/4885ALDH1A1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.